Vivos Therapeutics (VVOS) Asset Utilization Ratio (2021 - 2026)

Vivos Therapeutics (VVOS) has reported Asset Utilization Ratio for 6 consecutive years, with 0.85 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Asset Utilization Ratio rose 10.16% year-over-year to 0.85 in Q2 2026; TTM through Jun 2026 was 0.85, a 10.16% increase from a year earlier, with the FY2025 full-year figure at 0.86, down 25.34% from the prior year.
• Asset Utilization Ratio was 0.85 for Q2 2026 at Vivos Therapeutics, up from 0.78 in the prior quarter.
• Over five years, Asset Utilization Ratio peaked at 1.31 in Q4 2023 and troughed at 0.54 in Q1 2022.
• A 5-year average of 0.92 and a median of 0.96 in 2024 frame the typical range for Asset Utilization Ratio.
• Across the five-year window, Asset Utilization Ratio surged 120.75% in 2022 and tumbled 30.02% in 2025, its largest moves.
• Over 5 years, Asset Utilization Ratio stood at 1.0 in 2022, then surged by 31.44% to 1.31 in 2023, then retreated by 25.16% to 0.98 in 2024, then plunged by 30.02% to 0.69 in 2025, then rose by 23.74% to 0.85 in 2026.
• The last three Asset Utilization Ratio figures came in at 0.85 (Q2 2026), 0.78 (Q1 2026), and 0.69 (Q4 2025), per Business Quant data.